Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
KBLB Kraig Biocraft Laboratories Featured in Current Issue of Textile World
http://finance.yahoo.com/news/Kraig-Biocraft-Laboratories-iw-2795414298.html?x=0
ILNS Intellect Neurosciences Files New Patent Applications for Immunotherapy Methods to Target Abnormal Tau Protein in Treatment of Alzheimer's disease
http://finance.yahoo.com/news/Intellect-Neurosciences-Files-prnews-13479710.html?x=0
ILNS Form 10-Q INTELLECT NEUROSCIENCES, INC.
http://biz.yahoo.com/e/120202/ilns.pk10-q.html
ILNS Intellect Neurosciences Issues Letter to Shareholders
NEW YORK, Feb. 2, 2012 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCBB:ILNS.PK - News), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases today issued the following Letter to Shareholders from Dr. Daniel Chain, Chairman and CEO.
(Logo: http://photos.prnewswire.com/prnh/20111214/NY22484LOGO )
Dear Shareholder,
2011 was an exceptionally fruitful year for Intellect Neurosciences. We introduced two new innovative platform technologies, which will set the stage for the future direction of the company and offer significant potential to create value for the Company and our shareholders. We also ended the year with an improved balance sheet. As we enter 2012, we are excited by the prospect that our pioneering Alzheimer's disease immunotherapy ANTISENILIN® technology may be validated in the Phase 3 trials for Bapineuzumab, which are nearing completion. In addition, we expect to demonstrate proof-of-concept in our early stage programs: IN-N01-OX2, a compound of CONJUMAB-A, our antibody drug conjugate platform; and RV03, a compound of RECALL-VAX, and the first dual-acting Alzheimer's disease vaccine targeting both beta amyloid and tau proteins.
Of particular significance and importance to Intellect Neurosciences in 2011, we completed a transaction with ViroPharma for our OX1 program. ViroPharma is one of the leading biotechnology companies, and they have done a stellar job of capturing the majority of market share in an orphan indication. Commensurate with the transaction, we received an upfront payment of $6.5 million, and we have the potential to receive up to $120 million in regulatory milestone payments, in addition to a two-tiered royalty reaching double digits from future potential drug sales. ViroPharma will bear all of the costs of continued development and commercialization. Mr. Vincent Milano, ViroPharma's CEO, spoke enthusiastically about his company's plans to develop OX1 for Friedreich's Ataxia during his presentation at the JP Morgan Healthcare Conference in January 2012, indicating OX1 likely would enter Phase 2 clinical trials early in 2013. Mr. Milano expressed hope that OX1 would be at least as successful as ViroPharma's best-selling orphan drug, CINRYZE®, which reportedly generated more than $300 million in sales revenue last year. We could not be more pleased that ViroPharma chose Intellect Neurosciences' product for its next development program.
To ensure an ongoing pipeline of product candidates that have the potential to build shareholder value, we focused on developing other assets in our pipeline and further enriching our patent estate. We filed patent applications at the United States Patent and Trademark Office (USPTO) based on two new discoveries, which we believe will result in important next generation biologics for the treatment of Alzheimer's and other neurodegenerative diseases. Already we have received positive feedback from major pharmaceutical companies interested in specific drug products of these platform technologies. Discussions are commencing with potential partners, even at this early stage.
Pipeline Activities:
We introduced RV03 during 2011, a first-in-class Alzheimer's vaccine candidate, which targets the two proteins that are the hallmark features of the disease: beta amyloid, which accumulates in the brains of Alzheimer's patients and deposits as plaques on the surface of nerve cells, and abnormal tau proteins, which comprise intracellular neurofibrillary tangles. Although both beta amyloid and tau have been studied extensively on an individual basis with regard to their separate modes of toxicity, new light has been shed recently on their possible interactions and synergistic effects in Alzheimer's disease. Independent published studies have shifted our understanding of the role of tau in the pathogenesis of Alzheimer's disease towards being a crucial partner of beta amyloid. Of particular interest is the cleavage of tau protein by "executioner" caspases, which leads to a truncated form of the protein that is more toxic than the intact protein and can precede tangle formation.
It occurred to us that we could use our RECALL-VAX platform to generate an immune response specifically targeting this more toxic form of tau, known as delta tau. Moreover, since RECALL-VAX technology lends itself particularly well to a combined vaccine, we are using it to target both beta amyloid and delta tau, in each case taking advantage of the unique molecular signatures ("neoepitopes") formed by the cleavage of the precursor proteins. We are in the process of embarking on proof-of-concept studies for RV03 in a transgenic mouse model of Alzheimer's disease, which expresses both human beta amyloid and delta tau. We expect initial data by the end of 2012.
CONJUMAB-A is our novel proprietary antibody-empowering platform technology that we believe has the potential to yield a new class of improved therapeutics and diagnostics for treatment of Alzheimer's disease and other proteinopathies. The technology is based on antibody-drug conjugates (ADCs) that specifically target amyloid and amyloid-associated proteins, as well as associated toxicity, such as oxidative stress and inflammation leading to tissue damage. CONJUMAB-A is the first application of ADCs to treatment of neurodegenerative diseases and aims to capitalize on the significant advances made with ADCs in the field of oncology. CONJUMAB-A has the potential to improve on current methods of passive immunotherapy by increasing clearance of amyloid or amyloid-associated proteins while delivering potent cytoprotective molecules to sites of amyloidosis, and thus, reduce inflammation and oxidative stress.
CONJUMAB-A has potential application for treatment of several serious diseases, such as Alzheimer's, Parkinson's, Huntington's, Cerebral Amyloid Angiopathy, Frontotemporal Dementia, Progressive Supranuclear Palsy, Pick's disease, Creutzfeldt-Jakob disease and Cortical Basal Degeneration. It also may be effective in non-CNS indications, such as Age-Related Macular Degeneration, Glaucoma, and Peripheral Amyloidosis.
Intellect Neuroscience's lead CONJUMAB-A candidate is IN-N01-OX2, a non-activating, stabilized IgG4 humanized monoclonal antibody specific for beta amyloid protein conjugated to OX2, a small molecule with potent neuroprotective properties due to its dual activities as an anti-oxidant and protein aggregation inhibitor. We are developing IN-N01-OX2 as first-in-class treatment for retinal degeneration, notably age-related macular degeneration and glaucoma. The drug candidate also has potential applications for Alzheimer's disease and traumatic brain injury.
CONJUMAB-A offers us multiple opportunities for commercialization: For example, we may partner products developed internally by Intellect (e.g. IN-N01-OX2). Alternatively, we can license use of the technology to other companies that have different antibodies that would be suitable for development as new antibody drug conjugates in combination with OX2 or other small molecule. We may also partner with companies that have other neuroprotective small molecules for use in an antibody drug conjugate.
R&D Team:
Continuing with our operational goals to maintain a streamlined, effective team to manage our international virtual R&D activities, we have made two recent additions: Dr. Vadim Fedulov, Ph.D., an expert in transgenic mouse models of neurodegeneration, based in Copenhagen, Denmark, serves as Project Manager and Dr. Dan Shochat, Ph.D., based in San Francisco, serves as Consulting Vice President Non-Clinical Development.
Dr. Shochat is a pioneer in the antibody development field with more than 20 years of experience in the biotechnology industry. He has been instrumental in the invention and development of the approved in vivo tumor-imaging reagent CEA-Scan™ and led the team that obtained the first approved antibody-drug conjugate, Mylotarg™. He was pivotal to the development of Bexxar™, a radioiodinated antibody for the treatment of Non-Hodgkin's Lymphoma that was approved by the FDA in June 2003. In 2001 he joined Deltagen as Vice President of Pharmaceutical Development and in 2003 co-founded Celscia Therapeutics Inc., a therapeutic antibodies development company, which merged with KaloBios Therapeutics in January 2004 where he has held the position of Executive Vice President, Development.
Patent News:
We continue to devote considerable resources to our patent estate, including ongoing patent prosecution, defending existing patents and adding new patent applications to revitalize our patent portfolio. Of particular significance, we obtained a new patent in both the United States and Japan for our RECALL-VAX technology platform in 2011. In Europe, we filed an appeal in response to an opposition filed against us by Wyeth and Élan Pharmaceuticals with respect to our ANTISENILIN® patent estate. We remain confident of our ability to prevail in this process. In addition, we have additional divisional applications pending to further protect us. We obtained strong support for our patent prosecution in Europe and the U.S. from world-renown independent experts who provided written declarations explaining errors in the office actions against us. This support gives us good reason to believe we ultimately will be granted the patents we are seeking.
Current Period Financial Summary:
As of December 31, 2011, we had cash and cash equivalents of $1,053,880. Proceeds from the ViroPharma transaction were used to pay expenses related to the transaction, including payment of $1.3 million in licensing fees to our university research partners; $826,000 to consultants who helped secure the agreement; legal fees incurred in connection with executing the transaction; and payment of significant overdue accounts payable owed to contract research organizations, independent auditors, former independent directors and other vendors. The balance has been set aside for working capital.
Operating expenses for the three months ended December 31, 2011, increased by $3,173,825, to $3,924,828 from $751,003 for the comparable period last year. The increase in operating expenses was caused by an increase in both General and Administrative expenses primarily related to the ViroPharma transaction and an increase in Research and Development fees.
Other income (expenses) for the three months ended December 31, 2011, changed by $19,324,458, to income of $17,933,750 from a loss of $1,390,708 for the comparable period last year. The change primarily was due to a non-cash gain on the change in the value of derivative instruments and preferred stock liability and a reduction in interest expense.
Increased public awareness:
We have continued our efforts to increase public and investor awareness of Intellect Neurosciences through media outreach and other activities, including speaking at several international industry and investor conferences. Our activities and developments are frequently reported in the media, including several articles that have appeared in BioCentury, a professional online magazine that is read widely in the industry. These activities have contributed to the increased attention we have received from potential strategic partners. We will continue these activities in 2012.
2011 was a year of remarkable achievements for a company with the small size and limited resources of Intellect. These achievements have yielded our current licenses and rich pipeline that generates continued interest from major biotechnology and pharmaceutical companies.
Thank you for your continued support of Intellect Neurosciences and our important mission to create a world without Alzheimer's disease and other horrifying neurodegenerative diseases.
Sincerely,
Daniel G. Chain, PhD
Chairman & CEO
Safe Harbor Statement Regarding Forward-Looking Statements:
The statements in this release and oral statements made by representatives of Intellect relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Intellect's Annual Report on Form 10-K (file no. 333-128226), filed on October 13, 2011, and in our Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2011, filed on February 2, 2012.
Contact:
Jules Abraham
JQA Partners, LLC
917-885-7378
Jabraham@jqapartners.com
btw, deleted posts about MLXO are retrievable.
Technology is beautiful.
re: MLXO, a member's post: Wait....we're trading Deano for Elcheepo? Seriously? Nothing against elcheepo but I just always took his negative outlook on life and MLXO as humor. Now he/she's a moderator"?
RE: MLXO. Monkey see, Monkey do.
In other words, peeps watching MLXO buying may also buy, lol.
Hope the fox doesn't get the possum in MLXO
while the share price is rising.
MLXO shareholders are supporting themselves
but management, vice versa.
MLXO chart improvement in 2012.
5 day avg. crossed up and over 10 avg.
MLXO communication better kept private,
just like Michelex management CEO Sabir Saleem.
MSLP.OB MusclePharm Inks Deal With NFL Superstar, 49er All-Pro Patrick Willis
PR Newswire
DENVER, Jan. 12, 2012 /PRNewswire/ -- MusclePharm Corporation, a Nevada corporation ("MusclePharm" or the "Company") (OTCBB: MSLP.OB - News), an expanding U.S. nutritional supplement company, is pleased to announce that it has signed San Francisco 49er superstar linebacker Patrick Willis.
The NFL standout has been a perennial All-Pro selection and is also a five-time Pro Bowl selection.
A two-time All-American at Mississippi, the first-round draft pick of the 49ers in 2007 has quickly become one of the top defensive players in the NFL.
In fact, an ESPN.com expert vote, Willis was named the NFL's best linebacker and the fourth-best defensive player.
In addition to his tremendous on-field success, Willis' rigorous fitness regimen and noted work ethic also makes him an ideal match with MusclePharm and its healthy lifestyle vision.
Willis' social media following includes nearly 105,000 fans on Twitter as well, which fits in perfectly with MusclePharm's impressive and strong social media presence.
"I love the fact that I can partner with a company that is developing cutting edge products that help me train harder and perform to the best of my abilities," NFL Superstar Patrick Willis said. "MusclePharm takes the guess work out of using supplements because I know they take the time to test all their products above and beyond what is required for athletes. MusclePharm is the Athletes Company and I am excited to join the team."
MusclePharm, which is the official nutritional supplement provider of the Ultimate Fighting Championship (UFC), has also inked deals with NFL superstars Michael Vick and Chad Ochocinco in 2011.
MusclePharm continues to grow at an impressive rate as well, setting a monthly company sales record ($2,700,000) in November.
http://finance.yahoo.com/news/MusclePharm-Inks-Deal-With-prnews-3982603325.html?x=0
GNVC - Law Firm Brower Piven Announces Investigation of Investor Securities Fraud Against GenVec, Inc.
STEVENSON, Md.--(BUSINESS WIRE)-- The law firm of Brower Piven, A Professional Corporation, is investigating potential securities fraud claims against GenVec, Inc. (“GenVec”) (NASDAQ: GNVC - News) regarding whether GenVec may have issued materially false or misleading information to investors before announcing on March 29, 2011 that it was discontinuing its Phase III clinical trial of TNFerade in patients with locally advanced pancreatic cancer.
Brower Piven has been retained to commence a securities class action lawsuit on behalf of GenVec investors to recover investment losses. If you purchased or acquired GenVec securities between March 12, 2009 and March 29, 2010 and have suffered a loss on your investment, or if you believe you have information relating to the subject matter of our investigation, you may email or call Brower Piven, who will, without obligation or cost to you, attempt to answer your questions. You may contact Brower Piven by email at hoffman@browerpiven.com, by calling 410/415-6616, or by writing to Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and other class action cases of over 60 years.
Contact:
Brower Piven, A Professional Corporation
Stevenson, Maryland
Charles J. Piven, 410-415-6616
hoffman@browerpiven.com
http://finance.yahoo.com/news/Law-Firm-Brower-Piven-bw-642692649.html?x=0
Merry Xmas $b_rich$, et al.
Most charts of stock ideas appear unfavorable.
KBLB (.083) CMF about to turn positive.
GNBT PR today: Generex Biotech and Avanir Pharmaceuticals Look to Rally in 2012
The Paragon Report Provides Equity Research on Generex Biotechnology & Avanir Pharmaceuticals
NEW YORK, NY, Dec 12, 2011 (MARKETWIRE via COMTEX) -- The biotechnology industry has been a strong performer in 2011 as mergers and acquisitions and favorable legislation have propped up the sector. The domestic biotechnology industry has tapped into only a fraction of its several potential applications and is expected to grow to $146.2 billion in 2016, from an estimated $92.4 billion in 2011, according to a report from IBISWorld. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Generex Biotechnology Corporation GNBT -6.38% and Avanir Pharmaceuticals, Inc. AVNR -5.22% . Access to the full company reports can be found at:
www.paragonreport.com/GNBT
www.paragonreport.com/AVNR
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. Last month the company announced that the European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application for NUEDEXTA for the treatment of pseudobulbar affect (PBA).
NUEDEXTA was approved by the U.S. Food and Drug Administration in October 2010 for the treatment of PBA, a neurologic condition which is characterized by frequent outbursts of involuntary crying or laughing.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.
Generex Biotechnology Corporation is a development stage company engaged in the research and development of drug delivery systems and technologies for metabolic and immunological diseases. Last week shares of the company spiked after it announced that positive interim Phase 2 clinical data from its ongoing study of a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37) in HER-2 expressing breast cancer patients were presented at the 34th Annual CTRC-AACR.
Generex explains that its Ii-Key Hybrid technology platform entails the modification of fragments of antigens to increase their potency in stimulating critical members of the immune response, known as CD4+ T helper cells.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer
SOURCE: Paragon Financial Limited
http://www.marketwatch.com/story/generex-biotech-and-avanir-pharmaceuticals-look-to-rally-in-2012-2011-12-12